Page 942 - Cardiac Nursing

g
Pa
p90
18
e 9
6-9
0 P
a
M
20.
9
2
0
9
/
Apt
18
ar
d
qx
009
1
2
1:2
LWBK340-c41_p906-920.qxd 29/06/2009 11:20 PM Page 918 Aptara
41_
K34
LWB
20.
K34
6-9
LWB K34 0-c 41_ p90 6-9 20. qx d 2 9 / 0 6 / / 2 009 1 1:2 0 P M Pa g e 9 18 Apt ar a
009
6
0-c
918 PA R T V / Health Promotion and Disease Prevention
REFERENCES Center under Contract No. 290-02-0023, AHRQ Publication No. 07-
E010). Rockville, MD: Agency for Healthcare Research and Quality.
1. National Center for Complementary and Alternative Medicine. (2007). 24. McCraty, R., Atkinson, M., & Tomasino, D. (2003). Impact of work-
What is complementary and alternative medicine (CAM)? NCCAM place stress reduction program on blood pressure and emotional health
7
7
Publication No. D347. Retrieved February 10, 2008, from http://nccam. in hypertensive employees. Journal of Alternative and Complementary
nih.gov/health/whatiscam/ Medicine, 9(3), 355–369.
6
2. World Health Organization. (2007). Fact sheet No. 326. Retrieved April 25. Vempati, R. P., & Telles, S. (2002). Yoga-based guided relaxation reduces
6
1, 2008, from http://www.who.int/mediacentre/factsheets/fs326/en/ sympathetic activity judged from baseline levels. Psychology Report, 90(2),
3. Barnes, P. M., Powell-Griner, E., McFann, K., et al. (2004). Comple- 487–494.
mentary and alternative medicine use among adults: United States, 2002. 26. Mahajan, A. S., Reddy, K. S., & Sachdeva, U. (1999). Lipid profile of
7
7
Advanced Data, 27(343), 1–19. coronary risk subjects following yogic lifestyle intervention. Indian Heart
4. Eisenberg, D. M., Davis, R. B., Ettner, S. L., et al. (1998). Trends in al- Journal, 51(1), 37–40.
0
0
ternative medicine use in the United States, 1990–1997. JAMA, 280, 27. Manchanda, S. C., Narang, R., Reddy, K. S., et al. (2000). Retardation
1569–1575. of coronary atherosclerosis with yoga lifestyle intervention. Journal of the
5. Astin, J. A., Pelletier, K. R., Marie, A., et al. (2000). Complementary and Association of Physicians of India, 48(7), 687–694.
alternative medicine use among elderly persons: One-year analysis of a 28. Schmidt, T., Wijga, A., Von Zur Muhlen, A., et al. (1997). Changes in
Blue Shield Medicare supplement. Journal of Gerontology Series A: Bio- cardiovascular risk factors and hormones during a comprehensive resi-
logical Science and Medical Science, 55(1), M4–M9. dential three month kriya yoga training and vegetarian nutrition. Acta
6. Centers for Medicare & Medicaid Services. (1997). National health ex- Physiologica Scandinavia Supplement, 640, 158–162.
0
0
penditures survey. Retrieved April 20, 2008, from www.cms.hhs.gov/ 29. Vierling, W., Brand, N., Gaedcke, F., et al. (2003). Investigation of the
statistics/nhe pharmaceutical and pharmacological equivalence of different Hawthorn
7. Swartzman, L.C., Harshman, R. A., Burkell, J., et al. (2002). What ac- extracts. Phytomedicine, 10(1), 8–16.
counts for the appeal of complementary/alternative medicine, and what 30. Pittler, M. H., Guo, R., & Ernst, E. (2008). Hawthorn extract for treat-
makes complementary/alternative medicine alternative? Medical Decision ing chronic heart failure. Cochrane Database of Systematic Reviews, 23(1),
2
2
Making, 22, 431–450. CD005312.
8. Nahin, R. L., Dahlamer, J. M., Taylor, B. L., et al. (2007). Health be- 31. Schmidt, U., Kuhn, U., Ploch, M., et al. (1994). Efficacy of the
haviors and risk factors in those who use complementary and alternative Hawthorne (Crataegus) Preparation LI 132 in 78 patients with chronic
medicine. BioMed Central Public Health, 7(217), 1–9. congestive heart failure defined as NYHA functional class II. Phytomed-
7
7
9. Xu, K. T., & Farrell, T. W. (2007). The complementary and substitution icine, 1, 17–24.
between conventional and mainstream medicine among racial and eth- 32. Zapfe, G. (2001). Clinical efficacy of crataegus extract WS 1442 in con-
nic groups in the United States. Health Services Research, 42(2), gestive heart failure NYHA class II. Phytomedicine, 8, 262–266.
8
811–824. 33. Tauchert, M. (2002). Efficacy and safety of crataegus extract WS 1442 in
10. Burg, M. A., Kosch, S. G., Neims, A. H., et al. (1998). Personal use of comparison with placebo in patients with chronic stable New York Heart
alternative medicine therapies by health science center faculty. JAMA, Association class-III heart failure. American Heart Journal, 143,
280(18), 1563. 910–915.
g
g
11. Fontaine, K. L. (2000). Healing practices, alternative practices for nursing. 34. Daniele, C., Mazzanti, G., Pittler, M. H., et al. (2006). Adverse event
Upper Saddle River, NJ: Prentice-Hall. profile of Crataegus spp.: A systematic review. Drug Safety, 29(6),
12. Saydah, S. H., & Eberhardt, M. S. (2006). Use of complementary and 523–535.
alternative medicine among adults with chronic diseases: United States 35. Dwivedi, S., & Agarwal, M. P. (1994). Antianginal and cardioprotective
2002. The Journal of Alternative and Complementary Medicine, 12(8), effects of Terminalia arjuna, an indigenous drug, in coronary artery dis-
805–812. ease. Journal of the Association of Physicians of India, 42(4), 287–289.
13. Bell, R. A., Suerken, M. S., Grzywacz, J. G., et al. (2006). CAM use 36. Dwivedi, S., & Jauhari, R. (1997). Beneficial effects of Terminalia arjuna
9
9
among older adults age 65 and older with hypertension in the United in coronary artery disease. Indian Heart Journal, 49(5), 507–510.
States: General use and disease treatment. The Journal of Alternative and 37. Bharani, A., Ganguly, A., & Bhargava, K. D. (1995). Salutary effect of
e
e
Complementary Medicine, 12(9), 903–909. Terminalia Arjuna in patients with severe refractory heart failure. Inter-
9
9
14. Wood, M. J., Stewart, R. L., Merry, H., et al. (2003). Use of comple- national Journal of Cardiology, 49(3), 191–199.
mentary and alternative medical therapies in patients with cardiovascular 38. Rissanen, T., Voutilainen, S., Nyyssonen, K., et al. (2000). Fish oil-
disease. American Heart Journal, 145(5), 806–812. derived fatty acids, docosahexaenoic acid and docosapentaenoic acid, and
15. Ai, A. L., & Bolling, S. F. (2002). The use of complementary and alter- the risk of acute coronary events: The Kuopio ischaemic heart disease risk
2
2
native therapies among middle-aged and older cardiac patients. American factor study. Circulation, 102, 2677–2679.
Journal of Medical Quality, 17(1), 21–27. 39. Bucher, H. C., Hengstler, P., Schindler, C., et al. (2002). N-3 polyunsat-
7
7
16. Williamson, A. T., Fletcher, P. C., & Dawson, K. A. (2003). Comple- urated fatty acids in coronary heart disease: A meta-analysis of random-
mentary and alternative medicine: Use in an older population. Journal of ized controlled trials. American Journal of Medicine, 112, 298–304.
2
2
Gerontological Nursing, 29(5), 20–28. 40. Marchioli, R., Barzi, F., Bomba, E., et al. (2002). Early protection against
17. Montbriand, M. J. (2000). Senior and health professionals’ perceptions sudden death by n-3 polyunsaturated fatty acids after myocardial infarc-
and communication about prescriptions and alternative therapies. Cana- tion: Time-course analysis of the results of the Gruppo Italiano per lo
9
9
dian Journal on Aging, 19(1), 35–36. Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione.
5
18. Li, J. Z., Quinn, J. V., McCullock, C. E., et al. (2004). Patterns of com- Circulation, 105, 1897–1903.
5
plementary and alternative medicine use in ED patients and its associa- 41. GISSI Group (Gruppo Italiano per lo Studio della Sopravvivenza nel-
tion with healthcare utilization. American Journal of Emergency Medicine, l’Infarto miocardico). (1999). Dietary supplementation with n-3 polyun-
22(3), 187–191. saturated fatty acids and vitamin E after myocardial infarction: Results of
4
4
19. Brown, H. W. (2007). Complementary and alternative medicine: What the GISSI-Prevenzione trial. Lancet, 354, 447–455.
people 50 and older are using and discussing with their physicians. Wash- 42. Kromhout, D., Bosschieter, E. B., & de Lezenne Coulander, C. (1985).
ington, DC: AARP. The inverse relation between fish consumption and 20-year mortality
20. U.S. Department of Labor: Bureau of Labor Statistics. (2007). Chiro- from coronary heart disease. New England Journal of Medicine, 312(19),
practors. Retrieved May 28, 2008, from http://www.bls.gov/oco/pdf/ 1205–1209.
ocos071.pdf. 43. Daviglus, M. L., Stamler, J., Orencia, A. J., et al. (1997). Fish consump-
21. Kligler, B., & Lee, R. A. (2004). Integrative medicine: Principles for prac- tion and the 30-year risk of fatal myocardial infarction. New England
6
6
tice. New York: McGraw-Hill, Medical Publishers Division. Journal of Medicine, 336(15), 1046–1053.
22. Walters, J. D. (2002). The art and science of Raja Yoga: Fourteen steps to 44. Albert, C. M., Campos, H., Stampfer, M. J., et al. (2002). Blood levels
higher awareness. Delhi: Motilal Banarsidass Publishers. of long-chain n-3 fatty acids and the risk of sudden death. New England
6
23. Ospina, M. B., Bond, K., Karkhaneh, M., et al. (2007). Meditation prac- Journal of Medicine, 346, 1113–1118.
6
tices for health: State of the research. Evidence report/technology assessment 45. Albert, C. M., Hennekens, C. H., O’Donnell, C. J., et al. (1998). Fish
5
No. 155. (Prepared by the University of Alberta Evidence-based Practice consumption and risk of sudden cardiac death. JAMA, 279(1), 23–28.
5